Premium
Thymidine labeling index in epithelial ovarian cancer
Author(s) -
Salihoglu Y,
Bilir A,
Aydiner A,
Erkan M,
Tuzlali S,
Eralp Y
Publication year - 2001
Publication title -
international journal of gynecology and obstetrics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.895
H-Index - 97
eISSN - 1879-3479
pISSN - 0020-7292
DOI - 10.1016/s0020-7292(01)00455-6
Subject(s) - medicine , ovarian cancer , stage (stratigraphy) , gastroenterology , cancer , epithelial ovarian cancer , oncology , thymidine , gynecology , paleontology , biology , dna , genetics
Objective : The aim of this study is to determine the thymidine labeling index and its prognostic role in patients with ovarian cancer. Methods : Tumor cell proliferation in 32 patients with primary ovarian cancer admitted to Istanbul Medical Faculty, Department of Obstetrics and Gynecology, between 1993 and 1997 was investigated using the [ 3 H]thymidine labeling index (TLI). TLI results were compared with other clinical and histopathologic prognostic parameters. Results : The mean and median TLI values of the patients were 9.3±6.2% and 9.20% (range: 0.4–23.0%), respectively. Sixteen patients showed high proliferation rates (mean TLI: 14.3%). These patients had an overall survival rate of 46.7% at 3 years. The mean TLI level and overall survival at 3 years in the low proliferation rate group were 4.4 and 68.8%, respectively. Patients with a high TLI had a significantly shorter survival compared to those with a low TLI ( P <0.01). There was tendency towards a higher TLI with advanced stage ( P >0.05). However, there was no statistically significant correlation between TLI and other prognostic parameters. Conclusion : TLI may have a predictive value in determining the outcome of patients with ovarian cancer. Further larger scale studies are needed before definite conclusions can be made about its role as a prognostic factor in this disease.